Proteomics at 9-month high on securing US patent for diagnostic test
** Shares of Australia's Proteomics International Laboratories PIQ.AX rise as much as 7.6% to A$0.570, their highest level since late-February ** Medical technology firm secures U.S. patent for PromarkerEso diagnostic test for early diagnosis of esophageal cancer ** Stock is down 28.8% YTD, including the session's moves (Reporting by Anjali Singh in Bengaluru) ((anjali.singh2@thomsonreuters.com; ))
Recent news on Proteomics International Laboratories
See all newsBrief: Proteomics International Laboratories Says Restructure, Executive Appointment And Board Update
Brief: Proteomics International Laboratories Says Canadian Patent Secured For Promarkereso Diagnostic Test For Esophageal Adenocarcinoma
Appointment Of CEO And Managing Director
Brief: Proteomics International Laboratories Says US Patent Secured For Promarkereso Diagnostic Test
Proteomics at 9-month high on securing US patent for diagnostic test